{
    "2018-08-09": [
        [
            {
                "time": "2023-03-15",
                "original_text": "Factbox: U.S. companies with exposure to Russia",
                "features": {
                    "keywords": [
                        "U.S.",
                        "companies",
                        "exposure",
                        "Russia"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "general"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "Generic Drugmakers Struggle Despite U.S. Push for Copycats",
                "features": {
                    "keywords": [
                        "Generic",
                        "Drugmakers",
                        "Struggle",
                        "U.S.",
                        "Push",
                        "Copycats"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "Why Amgen is a Top Socially Responsible Dividend Stock (AMGN)",
                "features": {
                    "keywords": [
                        "Amgen",
                        "Socially",
                        "Responsible",
                        "Dividend",
                        "Stock"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-08-06",
                "original_text": "Examining Pfizerâ€™s Valuation as of August 6",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Valuation"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}